视神经脊髓炎的相关研究进展(3)
参见附件。
[8] Tomoko Okamoto, Masafumi Ogawa, Youwei Lin, et al. Treatment of neuromyelitis optica: current debate, in Therapeutic advances in neurological disorders. SAGE publications, 2008, 1(1): 43-52.
[9] Gavin Hudson, Catherine Mowbray, Joanna L.Elson, etc. Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease). Brain,2008,131:1-5.
[10] R.Bergamaschi, A.Ghezzi. Devic's neuromyelitis optica: clinical features and prognostic factors. Neurol Sci,2004,25:364-367.
[11] Lennon VAL, Weinshenker BG. Identification of a marker autoantibody of neuromyelitis optica. Neurology,2003,60:A519.
[12] Pittock SJ, Lennon VA, Jeromede Seze, et al. Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol, 2008, 65(1): 78-83.
[13] JA Cabrera-Gomez, A Saiz-Hinarejos, F Graus, et al. Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Multiple Sclerosis, 2008, 14(2): 248-251.
[14] 王莹, 张朝东. 视神经脊髓炎与脊髓型多发性硬化的临床研究.脑与神经疾病杂志, 2005, 13(5): 372-380.
[15] Brian G Weinshenker. Neuromyelitis optica: what it is and what it might be. The Lancet, 2003, 361: 889-890.
[16] 胡学强, 王玉鸽. 多发性硬化和视神经脊髓炎的治疗进展. 实用医院临床杂志, 2009,6(3):5-8.
[17] Bianca Weinstock-Guttman,Murali Ramanathan, Norah Lincoff, et al. Study of Mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol,2006,63:957-963.
[18] Anu Jacob, Brian G Weinshenker, Ivo Violich, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol,2008,65(11):1443-1448.
[19] 韦企平. 视神经脊髓炎. 中国实用眼科杂志,2007,25(3):243-245.
(收稿日期：2011-04-11)
(本文编辑：王春芸)
[8] Tomoko Okamoto, Masafumi Ogawa, Youwei Lin, et al. Treatment of neuromyelitis optica: current debate, in Therapeutic advances in neurological disorders. SAGE publications, 2008, 1(1): 43-52.
[9] Gavin Hudson, Catherine Mowbray, Joanna L.Elson, etc. Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease). Brain,2008,131:1-5.
[10] R.Bergamaschi, A.Ghezzi. Devic's neuromyelitis optica: clinical features and prognostic factors. Neurol Sci,2004,25:364-367.
[11] Lennon VAL, Weinshenker BG. Identification of a marker autoantibody of neuromyelitis optica. Neurology,2003,60:A519.
[12] Pittock SJ, Lennon VA, Jeromede Seze, et al. Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol, 2008, 65(1): 78-83.
[13] JA Cabrera-Gomez, A Saiz-Hinarejos, F Graus, et al. Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Multiple Sclerosis, 2008, 14(2): 248-251.
[14] 王莹, 张朝东. 视神经脊髓炎与脊髓型多发性硬化的临床研究.脑与神经疾病杂志, 2005, 13(5): 372-380.
[15] Brian G Weinshenker. Neuromyelitis optica: what it is and what it might be. The Lancet, 2003, 361: 889-890.
[16] 胡学强, 王玉鸽. 多发性硬化和视神经脊髓炎的治疗进展. 实用医院临床杂志, 2009,6(3):5-8.
[17] Bianca Weinstock-Guttman,Murali Ramanathan, Norah Lincoff, et al. Study of Mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol,2006,63:957-963.
[18] Anu Jacob, Brian G Weinshenker, Ivo Violich, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol,2008,65(11):1443-1448.
[19] 韦企平. 视神经脊髓炎. 中国实用眼科杂志,2007,25(3):243-245.
(收稿日期：2011-04-11)
(本文编辑：王春芸)
您现在查看是摘要介绍页，详见PDF附件。